Department of Pulmonary Medicine, University Hospital and University of Bern, Bern, Switzerland.
High Alt Med Biol. 2012 Dec;13(4):285-7. doi: 10.1089/ham.2012.1044.
High altitude pulmonary edema (HAPE) is a life-threatening complication of high altitude stay, which may occur above altitudes of 2500 m. This is a case report of a healthy 41-year-old man, presenting with recurrent HAPE at moderate altitude. Medical work-up revealed an idiopathic pulmonary artery hypertension (PAH), and specific vasoactive treatment was started. Despite treatment with an endothelin receptor antagonist, the patient deteriorated clinically. Subsequent medical reevaluation showed a significant progress of mediastinal lymphadenopathy. Due to the histological proof of sarcoidosis, the initial diagnosis of PAH had to be changed to sarcoidosis-related pulmonary hypertension. Initiation of immunosuppressive therapy with corticosteroids led to significant and clinically relevant decrease in pulmonary artery pressure, even allowing episodes of asymptomatic re-exposure to moderate altitude. This case describes HAPE as first manifestation of a sarcoidosis-related pulmonary hypertension with a very unusual and early presentation of the underlying disease in an apparently healthy mountaineer.
高原肺水肿(HAPE)是高原逗留的一种危及生命的并发症,可能发生在海拔 2500 米以上的地方。这是一例 41 岁健康男性的病例报告,他在中等海拔地区反复出现 HAPE。医学检查显示特发性肺动脉高压(PAH),并开始进行特定的血管活性治疗。尽管使用内皮素受体拮抗剂进行了治疗,但患者的临床状况仍在恶化。随后的医学重新评估显示纵隔淋巴结病明显进展。由于组织学证实为结节病,最初的 PAH 诊断必须更改为结节病相关肺动脉高压。开始使用皮质类固醇进行免疫抑制治疗,导致肺动脉压显著且具有临床相关性降低,甚至允许无症状再次暴露于中等海拔。本病例描述了 HAPE 作为结节病相关肺动脉高压的首发表现,在一个明显健康的登山者中,这种潜在疾病的表现非常不寻常且较早。